Safety and efficacy of early medical abortion at home between 10+0 and 11+6 weeks' gestation: a retrospective review
Open Access
- 2 October 2025
- journal article
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 57-62
Abstract
Introduction: Since 2020, legislation in Britain has allowed both mifepristone and misoprostol to be taken at home for early medical abortion (EMA). In England and Wales, legislation restricts this to 9+6 weeks, but in Scotland this is permitted up to 11+6 weeks. Data on the outcomes of EMA at home >10 weeks’ gestation is limited and so we aimed to establish the safety and efficacy of this in comparison with EMA in a hospital setting. Methods: We conducted a retrospective review from our abortion service in Edinburgh, Scotland of outcomes of EMA at home versus hospital between 10+0 and 11+6 weeks' gestation over the 5-year period April 2020–March 2025. The primary outcome was complete abortion rate. Secondary outcomes were rates of incomplete abortion, ongoing pregnancy and serious complications. Results: A total of 371 EMAs occurred at this gestation (n=258 home, n=113 hospital). Complete abortion rates were not statistically significantly different between groups: 251/258 (97%) (95% CI: 94% to 99%) at home and 110/113 (97%) (95% CI: 92% to 99%) in hospital. Neither incomplete abortion rates (home: 4/258, 1.6%; hospital: 3/113, 2.6%) nor ongoing pregnancy rates (home: 3/258, 1.2%; hospital: 0/113, 0%) were significantly different between groups. There was one case of haemorrhage requiring transfusion and three cases of infection receiving intravenous antibiotics, all in the at home group. Conclusions: EMA at home between 10+0 and 11+6 weeks has the same high efficacy and safety as when conducted in hospital. Action is needed to extend EMA at home after 10 weeks' gestation to women across the rest of the UK and beyond.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 16 references indexed in Scilit:
- Using telemedicine to improve early medical abortion at home (UTAH): a randomised controlled trial to compare telemedicine with in-person consultation for early medical abortionBMJ Open, 2023
- Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancyActa Obstetricia et Gynecologica Scandinavica, 2023
- Effectiveness, safety and acceptability of no‐test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort studyBJOG: An International Journal of Obstetrics & Gynaecology, 2021
- A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64–70 and 71–77 days of gestation: A retrospective chart reviewContraception, 2020
- Information on early medical abortion for women using an audiovisual animation vs face‐to‐face consultation: A consortium randomized and quasi‐randomized trialActa Obstetricia et Gynecologica Scandinavica, 2020
- A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64–70 days and 71–77 days of gestationContraception, 2020
- Expanding a woman's options to include home use of misoprostol for medical abortion up until 76 days: an observational study of efficacy and safetyActa Obstetricia et Gynecologica Scandinavica, 2019
- Safety and acceptability of medical abortion through telemedicine after 9 weeks of gestation: a population‐based cohort studyBJOG: An International Journal of Obstetrics & Gynaecology, 2018
- Medical abortion reporting of efficacy: the MARE guidelinesContraception, 2016
- Medical abortion at 9–13 weeks' gestation: a review of 1076 consecutive casesContraception, 2005